Anti-JC-virus antibody prevalence in a German MS cohort

Clemens Warnke; Thomas Dehmel; Anita Posevitz-Fejfár; Andrew Chan; Achim Berthele; Stephan Schmidt; Judith Haas; Helena C. Kronsbein; Florian Seitz; Björn Tackenberg; Mathias Mäurer; Kathrin Gerbershagen; Volker Limmroth; Ortwin Adams; Hans Peter Hartung; Ralf Gold; Bernhard Hemmer; Heinz Wiendl; Bernd C. Kieseier

doi:10.1177/1352458511429955

Anti-JC-virus antibody prevalence in a German MS cohort

Clemens Warnke, Thomas Dehmel, Anita Posevitz-Fejfár, Andrew Chan, Achim Berthele, Stephan Schmidt, Judith Haas, Helena C. Kronsbein, Florian Seitz, Björn Tackenberg, Mathias Mäurer, Kathrin Gerbershagen, Volker Limmroth, Ortwin Adams, Hans Peter Hartung, Ralf Gold, Bernhard Hemmer, Heinz Wiendl, Bernd C. Kieseier

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Original language	English
Pages (from-to)	1054-1055
Number of pages	2
Journal	Multiple Sclerosis Journal
Volume	18
Issue number	7
DOIs	https://doi.org/10.1177/1352458511429955
State	Published - Jul 2012

Access to Document

10.1177/1352458511429955

Cite this

Warnke, C., Dehmel, T., Posevitz-Fejfár, A., Chan, A., Berthele, A., Schmidt, S., Haas, J., Kronsbein, H. C., Seitz, F., Tackenberg, B., Mäurer, M., Gerbershagen, K., Limmroth, V., Adams, O., Hartung, H. P., Gold, R., Hemmer, B., Wiendl, H., & Kieseier, B. C. (2012). Anti-JC-virus antibody prevalence in a German MS cohort. Multiple Sclerosis Journal, 18(7), 1054-1055. https://doi.org/10.1177/1352458511429955

@article{257b4899c0284fb79767b9949fdc3497,

title = "Anti-JC-virus antibody prevalence in a German MS cohort",

author = "Clemens Warnke and Thomas Dehmel and Anita Posevitz-Fejf{\'a}r and Andrew Chan and Achim Berthele and Stephan Schmidt and Judith Haas and Kronsbein, {Helena C.} and Florian Seitz and Bj{\"o}rn Tackenberg and Mathias M{\"a}urer and Kathrin Gerbershagen and Volker Limmroth and Ortwin Adams and Hartung, {Hans Peter} and Ralf Gold and Bernhard Hemmer and Heinz Wiendl and Kieseier, {Bernd C.}",

note = "Funding Information: This work was supported by grants from the German Ministry for Education and Research (BMBF, {\textquoteleft}German Competence Network Multiple Sclerosis{\textquoteright} (KKNMS), Natalizumab-Pharmakovigilanzstudie, grant number 01GI1002). CW is supported by an ECTRIMS fellowship stipend. Funding Information: TD, AP-F, CW, HCK and OA declare no conflicts of interest. AB, BCK, H-PH, VL, JH, SS, RG and HW have received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Health Care, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis, and TEVA Neuroscience. BT has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Health Care, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis and TEVA Neuroscience. MM has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis, Talecris and TEVA Neurosciences. AC has received research support from Bayer Vital, Biogen Idec, Merck Serono and Novartis. Has received compensation for advisory boards or lectures from Bayer Vital, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva. KG received travel expenses and honoraria as speaker from Bayer Health Care and Sanofi Aventis. BH has served on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Roche, Novartis and Merck Serono; serves as a consultant for Gerson Lehrman Group; and has received research support from Bayer Schering Pharma, Biogen Idec, Roche, Novartis, Merck Serono, Metanomics Health GmbH, Protagen AG, Deutsche Forschungsgemeinschaft (DFG), Bundesministerium f{\"u}r Bildung und Forschung (BMBF) and Hertie Foundation.",

year = "2012",

month = jul,

doi = "10.1177/1352458511429955",

language = "English",

volume = "18",

pages = "1054--1055",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "7",

}

Warnke, C, Dehmel, T, Posevitz-Fejfár, A, Chan, A, Berthele, A, Schmidt, S, Haas, J, Kronsbein, HC, Seitz, F, Tackenberg, B, Mäurer, M, Gerbershagen, K, Limmroth, V, Adams, O, Hartung, HP, Gold, R, Hemmer, B, Wiendl, H & Kieseier, BC 2012, 'Anti-JC-virus antibody prevalence in a German MS cohort', Multiple Sclerosis Journal, vol. 18, no. 7, pp. 1054-1055. https://doi.org/10.1177/1352458511429955

TY - JOUR

T1 - Anti-JC-virus antibody prevalence in a German MS cohort

AU - Warnke, Clemens

AU - Dehmel, Thomas

AU - Posevitz-Fejfár, Anita

AU - Chan, Andrew

AU - Berthele, Achim

AU - Schmidt, Stephan

AU - Haas, Judith

AU - Kronsbein, Helena C.

AU - Seitz, Florian

AU - Tackenberg, Björn

AU - Mäurer, Mathias

AU - Gerbershagen, Kathrin

AU - Limmroth, Volker

AU - Adams, Ortwin

AU - Hartung, Hans Peter

AU - Gold, Ralf

AU - Hemmer, Bernhard

AU - Wiendl, Heinz

AU - Kieseier, Bernd C.

N1 - Funding Information: This work was supported by grants from the German Ministry for Education and Research (BMBF, ‘German Competence Network Multiple Sclerosis’ (KKNMS), Natalizumab-Pharmakovigilanzstudie, grant number 01GI1002). CW is supported by an ECTRIMS fellowship stipend. Funding Information: TD, AP-F, CW, HCK and OA declare no conflicts of interest. AB, BCK, H-PH, VL, JH, SS, RG and HW have received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Health Care, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis, and TEVA Neuroscience. BT has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Health Care, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis and TEVA Neuroscience. MM has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis, Talecris and TEVA Neurosciences. AC has received research support from Bayer Vital, Biogen Idec, Merck Serono and Novartis. Has received compensation for advisory boards or lectures from Bayer Vital, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva. KG received travel expenses and honoraria as speaker from Bayer Health Care and Sanofi Aventis. BH has served on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Roche, Novartis and Merck Serono; serves as a consultant for Gerson Lehrman Group; and has received research support from Bayer Schering Pharma, Biogen Idec, Roche, Novartis, Merck Serono, Metanomics Health GmbH, Protagen AG, Deutsche Forschungsgemeinschaft (DFG), Bundesministerium für Bildung und Forschung (BMBF) and Hertie Foundation.

PY - 2012/7

Y1 - 2012/7

UR - http://www.scopus.com/inward/record.url?scp=84863202229&partnerID=8YFLogxK

U2 - 10.1177/1352458511429955

DO - 10.1177/1352458511429955

M3 - Letter

C2 - 22740609

AN - SCOPUS:84863202229

SN - 1352-4585

VL - 18

SP - 1054

EP - 1055

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 7

ER -

Anti-JC-virus antibody prevalence in a German MS cohort

Access to Document

Other files and links

Cite this